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Abstract
Growth pattern and nutritional intake as predictors 
of retinopathy of prematurity
Background Retinopathy of prematurity (ROP) is a sight-threatening disease that 
affects extremely preterm and very preterm infants. Approximately 5–10% of in-
fants screened for ROP go on to develop severe ROP that requires treatment. To 
minimize unnecessary screening procedures, which can be stressful for these fragile 
infants, it is important to identify new risk factors and predictors that better de-
termine which infants are at high risk for ROP. The objective of this study was to 
investigate growth pattern (peri- and postnatal weight gain) and nutritional intake 
as risk factors for severe ROP.
Methods WINROP (Weight, insulin-like growth factor 1, neonatal, retinopathy of 
prematurity) is a web-based surveillance system that aims to identify infants at high 
risk of ROP based on their birth weight (BW), gestational age (GA), and postnatal 
weight gain. In all cohorts that we studied, BW, GA, gender, and maximum ROP 
stage and ROP treatment were retrospectively retrieved from hospital records. In 
Paper I, we validated WINROP in a Swedish population-based cohort of extremely 
preterm infants (born at GA <27 weeks) (n=407). This cohort, called the EXPRESS 
cohort, was further evaluated in Paper IV in relation to nutritional intake and the 
correlation with severe ROP. In Paper II, the association between infant weight stan-
dard deviation scores (WSDS) at first sign of ROP and ROP requiring treatment was 
evaluated in a Gothenburg cohort screened for ROP (n=147). In Paper III, the birth 
weight standard deviations score (BWSDS) was calculated in 5 cohorts (n=2941) 
that were previously included in WINROP studies; Paper III assessed the impact of 
low birth weight as a risk factor for severe ROP.
Results WINROP correctly identified 96% (45/47) of infants who required treat-
ment for ROP in an extremely preterm cohort. Low weight (p=0.001) and low 
WSDS at first detection of ROP (p=0.002) were risk factors for severe ROP. Low 
BWSDS (p<0.001) was a risk factor for severe ROP for all preterm infants; however, 
the impact of low BWSDS increased with increasing GA. In addition, low energy 
intake (p<0.01) during the first four weeks of life was associated with the develop-
ment of severe ROP (p<0.01).
Conclusions Weight at birth and postnatal weight gain can be useful predictors for 
severe ROP as can weight at first detection of ROP. In addition, low energy intake 
during the first four weeks of a preterm infant’s life may be associated with later 
severe ROP.
Keywords: birth weight, nutrition, preterm infant, retinopathy of prematurity, risk 
factor, weight gain.
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Sammanfattning på svenska
Bakgrund
Med för tidig födelse, menar vi födelse mer än tre veckor före beräknad fullgången 
graviditet (40 veckor). I världen föds årligen ca 15 miljoner barn för tidigt. Allt fler 
barn som föds för tidigt överlever idag världen över. Ju omognare barnet är då det 
föds desto svårare är det för barnet att överleva eftersom många av barnets organ 
inte är fullt utvecklade. Omhändertagande av barnet första levnadstiden är viktig 
för barnets överlevnad och kommande livskvalitet, ju bättre vi kan hjälpa barnet att 
anpassa sig till världen utanför mammas mage desto större chans har barnet till ett 
gott liv.
Prematuritetsretinopati
Ett av de organ som inte är färdigutvecklat om barnet föds för tidigt är ögat och dess 
näthinna. Prematuritetsretinopati (ROP) är en synhotande ögonsjukdom som kan 
drabba barn som föds mycket omogna. Vid ROP utvecklas inte blodkärlen i näthin-
nan normalt. Vid den allvarligaste formen av ROP har onormala blodkärl bildats 
i näthinnan. Dessa onormala blodkärl kan orsaka blödningar i ögat, dragningar i 
näthinnan och i värsta fall näthinneavlossning, vilket kan leda till blindhet. Det är 
därför viktigt att allvarlig ROP upptäcks och behandlas i tid. Den mest använda 
behandlingen för att förebygga näthinneavlossning är laserbehandling.
För att identifiera de barn som behöver behandlas för synhotande ROP görs 
upprepade ögonundersökningar, s.k. ROP screening av för tidigt födda barn. I 
Sverige och i många andra länder undersöks alla barn som fötts före 31 graviditets-
veckor rutinmässigt i ett ROP screening program. Cirka 1000 barn per år genomgår 
ROP screeningen i Sverige. Barnen ögonundersöks vanligen varje/varannan vecka 
från graviditetsvecka 31 tills näthinnan är färdigutvecklad eller tills behandling 
krävs. Endast ca 5-10 % av de barn som ögonundersöks behöver behandling för 
allvarlig ROP. Ögonundersökningen kan vara mycket påfrestande för barnet.
Barnets omognad vid födelse är den viktigaste riskfaktorn för ROP, men även andra 
faktorer kan öka risken som till exempel exponering för höga och ojämna syrgasniv-
åer, övrig sjuklighet och infektioner. 
Tidig tillväxt
Under senare år har dålig tidig tillväxt identifierats som ytterligare en riskfaktor 
för ROP. Ju sämre barnet växer under sina första levnadsveckor desto större risk för 
ROP. Vid Göteborgs universitet har ett webbaserat system, kallat WINROP (www.
winrop.com), utvecklats för att identifiera de barn som växer dåligt och har störst 
risk att utveckla allvarlig ROP. Genom att en gång i veckan programmera in bar-
nets vikt i WINROP, beräknar WINROP om barnet har en hög risk att utveckla 
allvarlig ROP och larmar om så är fallet.
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Nutrition
En annan nyupptäckt riskfaktor för ROP är otillräcklig näringstillförsel under bar-
nets första levnadsveckor. För tidigt födda barn har ett stort behov av näring för att 
växa. Det är dock svårt att tillgodose detta behov eftersom bl.a. magtarmkanalen är 
omogen hos barnet. Ett för tidigt fött barn har heller inte utvecklat någon sugreflex 
så näringen måste från början ges via blodet eller via en sond.
Syfte 
Samtliga studier i den här avhandlingen har genomförts i syfte att förbättra iden-
tifieringen av de barn som har allra störst risk att utveckla allvarlig ROP. Syftet var 
framförallt att minimera antalet påfrestande ögonundersökningar för de barn som 
har mindre risk att få allvarlig ROP. Tidig identifiering av riskbarn medför att dessa 
kan följas extra noggrant.
Studiepopulation och metod
EXPRESS studien inkluderar alla barn födda extremt för tidigt, före graviditets-
vecka 27, i Sverige under åren 2004-2007. EXPRESS barnen studeras i artikel I och 
IV samt delvis i artikel III. I artikel II studeras barn i Göteborgsregionen under åren 
2011-2012 som genomgått ROP screening. I artikel III studeras 5 kohorter; 
3 svenska samt 2 amerikanska, där alla barn har genomgått ROP screening och 
ingått i tidigare WINROP studier.
Resultat
I denna avhandling konfirmerar vi att WINROP är ett tillförlitligt hjälpmedel vid 
ROP screening av extremt för tidigt födda barn. Vi visar också att barnets vikt vid 
första tecken till ROP kan användas för att prediktera synhotande ROP. Vi klargör 
att låg vikt/tillväxthämning vid födelse är en riskfaktor för allvarlig ROP, men med 
varierande genomslagskraft, som påverkar framför allt de något ”mer mogna” 
extrem prematur födda barnen (födda efter graviditetsvecka 26). Låg näringstillför-
sel under de första veckorna i livet är associerat med senare allvarlig ROP.
Slutsats
Genom att analysera det för tidigt födda barnets födelsevikt och viktuppgång efter 
födelse kan vi erhålla värdefull information om barnets framtida risker för att ut-
veckla synhotande ROP. Genom att optimera barnets tidiga näringstillförsel kan vi 
möjligen minska risken för allvarlig ROP.
Klinisk betydelse
De ögonundersökningar som görs för att identifiera allvarlig ROP är ofta påfrestande 
för barnet. Kan vi individualisera ROP screening med nya metoder och screening 
program och med större säkerhet identifiera de barn som har störst risk att utveckla 
allvarlig ROP, så kan vi bespara barnen med mindre risk onödiga påfrestande ögo-
nundersökningar.
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Abbreviations
AP ROP Aggressive posterior retinopathy of prematurity
AUC  Area under the curve
BPD  Bronchopulmonary dysplasia 
BW  Birth weight
BWSDS  Birth weight standard deviation score
CHOP   Children’s Hospital of Philadelphia
CI  Confidence interval
CRIB  Clinical risk index for babies
DHA  Docosahexaenoic acid
EXPRESS Extremely preterm infants in Sweden study
GA  Gestational age
EPA  Eicosapentaenoic acid
EPO  Erythropoietin
IGF-I  Insulin-like growth factor I
IVH  Intraventricular hemorrhage
LCPUFA Long-chain polyunsaturated fatty acids
NEC  Necrotizing enterocolitis
NICU  Neonatal intensive care unit
OR  Odds ratio
PDA  Patent ductus arteriousus
PMA  Postmenstrual age
ROC  Receiver operating characteristic
SDS  Standard deviation score
SGA  Small for gestational age
ROP  Retinopathy of prematurity
WHO  World health organization
WINROP Weight, insulin-like growth factor 1, neonatal, 
  retinopathy of prematurity 
WSDS  Weight standard deviation score
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Introduction
Introduction
The preterm infant
A preterm infant is defined as an infant that is born at less than 37 weeks of ges-
tation. Globally, about 15 million infants are born preterm each year according 
to a 2012 World Health Organization (WHO) report1. Prematurity is the world’s 
leading cause of newborn death within the first four weeks of life and causes about 
1 million newborn deaths each year. Approximately 10% of births worldwide are 
considered preterm2. 
Based on gestational age (GA), preterm infants are sub-grouped as follows:
•	 Moderate to late preterm (GA 32 to 37 weeks)
•	 Very preterm (GA 28 to 32 weeks)
•	 Extremely preterm (GA <28 weeks)
In recent decades, the survival rate of preterm infants has improved rapidly as the 
result of advanced peri- and postnatal care in countries with high-quality neonatal 
intensive care units (NICUs)3,4. Medical improvements have extended the limit of 
viability so that infants born as early as GA 22–23 weeks can survive. Annually, 
approximately 5.4% or 800 000 infants are born before GA 28 weeks (extremely 
preterm)5.
In the third trimester, i.e. from the 29th week of gestation, the fetus undergoes in-
tense growth and maturation as preparation for the transition from intrauterine to 
extrauterine life. Therefore, infants who are born extremely preterm are often poorly 
equipped to manage the extrauterine environment since vital alterations have not 
yet occurred in their immature organs. The preterm infant’s first weeks of life are 
frequently complicated due to conditions and diseases that are correlated with im-
maturity (Figure 1)6.
Figure 1. Mio is a very preterm boy who was born at 30 weeks and 6 days of gestation 
with a birth weight of 1350 g. ©Stina Fahlén
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tense growth and maturation as preparation for the transition from intrauterine to 
extrauterine life. Therefore, infants who are born extremely preterm are often poorly 
equipped to manage the extrauterine environment since vital alterations have not 
yet occurred in their immature organs. The preterm infant’s first weeks of life are 
frequently complicated due to conditions and diseases that are correlated with im-
maturity (Figure 1)6.
Figure 1. Mio is a very preterm boy who was born at 30 weeks and 6 days of gestation 
with a birth weight of 1350 g. ©Stina Fahlén
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Retinopathy of prematurity
The retinal vasculature is not fully developed before full term gestation at ~40 weeks. 
Retinopathy of prematurity (ROP), a potentially blinding disease, arises when ab-
normal vascularization occurs in the maturing retina. Accordingly, in order to un-
derstand the pathogenesis of ROP, it is important to first understand normal retinal 
development and vascularization.
Normal retinal vascularization 
The fetal eye has three major vascular systems: the hyaloid, the choroidal, and the 
retinal vasculature. The hyaloid vasculature gradually undergoes near-complete re-
gression in the developing eye. In the maturing fetal retina, the choroid provides 
the retina with nutrients and oxygen by diffusion until the retinal vascularization is 
fully developed. Vasculogenesis (the formation and differentiation of the embryotic 
vascular system) in the retina starts at ~12 weeks of gestation and is completed at ~21 
weeks of gestation, while angiogenesis (the formation and differentiation of blood 
vessels) starts at ~17 weeks of gestation7,8. The primitive retinal vessels emerge from 
the optic disc and extend/spread outward to the peripheral retina. The retina is fully 
vascularized at ~36 weeks of gestation in the periphery on the nasal side and at ~40 
weeks on the temporal side9. It has been proposed that the vascularization of the 
maturing retina is initiated by the increased metabolic demands of the developing 
neural retina. As the retinal neurons develop and thicken, the retinal demands for 
oxygen exceed the supply from the underlying choroid. This leads to up-regulation 
of vasoactive growth factors such as vascular endothelial growth factor (VEGF) and 
erythropoietin (EPO), which in turn stimulates new retinal vessel growth10,11.
Pathogenesis of retinopathy of prematurity
The hypothesis of oxygen toxicity and the concept of ROP as a two-phase disease 
were presented by Ashton in 1954. Ashton showed through animal experiments 
that excessive oxygen, termed hyperoxia, leads to vessel loss (phase I) followed by 
hypoxia-mediated vasoproliferation (phase II)12.
Phase I of retinopathy of prematurity
Phase I of ROP is characterized by impaired retinal vessel growth and the loss of pre-
viously formed vessels, phenomena that have been attributed mainly to hyperoxia. 
Specifically, the preterm infant is born into an oxygen-rich extrauterine environment 
that is thought to cause retinal hyperoxia. Hyperoxia leads to down-regulation of 
vasoactive growth factors, such as VEGF. Decreased VEGF levels and low levels of 
other growth factors, such as insulin-like growth factor I (IGF-I), that are the result 
of preterm birth result in arrested retinal vessel growth and in vessel loss12,13. How-
ever, retinal oxygenation has not been measured in preterm infants. Phase I of ROP 
occurs approximately from birth to GA 30 weeks.
Phase II of retinopathy of prematurity
Phase II of ROP occurs as the preterm infant matures. As the retinal neurons de-
velop, their demand for oxygen increases, resulting in localized hypoxia in the avas-
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cular retina. This hypoxia causes up-regulation of VEGF levels and EPO, leading 
to unregulated vessel growth and vasoproliferation11,14. Vasoproliferation can cause 
fibrosis, retinal traction, and, in the worst-case scenario, retinal detachment and 
blindness. Phase II occurs at approximately from GA 31 weeks (Figure 2).
Figure 2. Development of retinopathy of prematurity (ROP). Up and down-regulation 
of vasoactive growth factors such as vascular endothelial growth factor (VEGF), insulin-
like growth factor I (IGF-I) and erythropoietin (EPO) due to hyperoxia and  hypoxia are 
important actors in the development of ROP.
Classification of retinopathy of prematurity
ROP is classified by stage according to disease severity (ROP stages 0 to 5) and by 
zone according to the location of ROP in the retina (zones I to III). 
Stages to classify the severity of disease
•	 Stage 1: A demarcation line, a thin and flat white line, is seen between the 
vascular and avascular retina.
•	 Stage 2: A ridge, an elevation of the retina, is seen in the region of the demar-
cation line.
•	 Stage 3: Extraretinal vasoproliferation extends from the ridge.
•	 Stage 4: Partial retinal partial retinal detachment. 
•	 Stage 5: Total retinal detachment.  
Zones to define the location of the disease
Zone I is the most central part of the retina, and zone III is the most peripheral part 
of the retina (Figure 3)15.
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Figure 3. Retinal zones when classifying retinopathy of prematurity (ROP).
In clinical practice, ROP is often described as follows: no ROP (ROP stage 0), mild 
ROP (ROP stages 1–2), and severe ROP (ROP stages 3–5). Mild stages of ROP 
frequently regress spontaneously. When the disease progresses to ROP stage 3, a sub-
stantial proportion of cases continue to progress to sight-threatening ROP. Accord-
ingly, treatment must be initiated as soon as possible. ‘Plus disease’ is a term used 
to describe an additional sign of ominous activity i.e. the finding that the central 
retinal vessels are dilated and tortuous. Aggressive posterior ROP (AP ROP) is an 
especially severe, rapidly progressive form of ROP that is characterized by prominent 
plus disease and by a flat network of neovascularization in zone I or in posterior zone 
II. If untreated, AP ROP usually progresses rapidly to retinal detachment, generally 
without developing through the classical ROP stages15.
The international recommendations for ROP treatment are based on the following 
criteria: the stage of ROP, the zone in which ROP is detected, and whether plus 
disease is detected16.
The term ‘ROP type 1’ is frequently used when any of these treatment criteria are 
fulfilled. Severe ROP that almost fulfills the treatment criteria is called ROP type 
2. Frequent screening examinations, i.e. examinations conducted twice a week, are 
warranted for ROP type 2.
Retinopathy of prematurity type 1: 
•	 ROP of any stage is present in zone I with plus disease;
•	 ROP stage 3 is present in zone I without plus disease;
•	 ROP stage 2 or 3 is present in zone II with plus disease.
Retinopathy of prematurity type 2:
•	 ROP stage 1 or 2 in zone I without plus disease;
•	 ROP stage 3 in zone II without plus disease.
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Treatment for retinopathy of prematurity
For many years, laser treatment has been the treatment of choice for avascular retina. 
The purpose of laser treatment is to destroy the avascular hypoxic retina to reduce 
further up-regulation of VEGF, the treated areas of the retina are permanently dam-
aged. Current recommendations specify that when the established treatment criteria 
for ROP type 1 are fulfilled, treatment should be initiated within 48 hours. In recent 
years, intravitreal injection of anti-VEGF antibodies has also emerged as an alterna-
tive treatment for central disease (zone 1) and AP ROP, although this remains an 
off-label application. Prolonged clinical follow-up may be warranted to those infants 
who have received anti-VEGF treatment because of the possibility of delayed recur-
rence of ROP18,19. Notably, neither the appropriate dose of anti-VEGF molecules nor 
the potential long-time side effects of anti-VEGF injections have been established. 
There have been reports that anti-VEGF agents can be measured in serum at least 8 
weeks following an intravitreal injection in preterm infants and animals, and pos-
sibly have an adverse effect on other developing organs20,21. In Sweden, anti-VEGF 
injection is currently used primarily when laser treatment has been unsuccessful.
In some middle-income settings, anti-VEGF injections have become first-line treat-
ment, since laser equipment and laser-trained ophthalmologists are not always avail-
able.
Sequelae of retinopathy of prematurity
In high-income settings such as Sweden, only a few percent of infants who are 
screened for ROP become blind (visual acuity <0.1) or severely visually impaired 
(visual acuity <0.3) due to ROP22. However, in middle-income settings, the risk of 
blindness or visual deficit due to ROP is higher. Gilbert et al. reports that in middle 
income settings, such as in Argentina, Cuba and the Czech Republic with fewer 
high level NICUs up to 60% of childhood blindness may be due to ROP. While the 
quality of neonatal care is improving, not all NICUs have ROP screening programs, 
adequate screening equipment, and ophthalmologists who are trained to detect and 
treat ROP23. Hence, many infants in middle-income settings become blind without 
ever being examined by an ophthalmologist5. Zepeda-Romero et al. reported that in 
Guadalajara city, Mexico, only 50% of the NICU’s had a regular ROP program. In 
schools for the visually impaired in Guadalajara city more than 40% of the children 
(under the age of 5 years) were blind due to ROP. The majority of these infants had 
not been treated for ROP24.
Even though severe ROP can be treated successfully and most blindness due to 
ROP and preterm birth can be prevented, ROP can have additional long-term eye 
sequelae. Refractive errors, anisometropia, subnormal visual acuity, and strabismus 
more frequently affect preterm infants with ROP, especially if ROP treatment has 
been performed. Infants born preterm without ROP are also at higher risk of devel-
oping these ophthalmological conditions than infants born at full term25-28. Preterm 
infants who have other neurological complications, such as intraventricular hem-
orrhage (IVH), cerebral palsy, and/or mental retardation, also have an additional 
increased risk of ophthalmological problems, including visual perception deficien-
cies27,29,30.
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Severe ROP has also been associated with poor neurodevelopmental functional out-
come, i.e. motor and cognitive impairment and severe hearing loss31,32. Systemic 
complications such as increased blood pressure have also been associated with severe 
ROP33.
Most pediatric ophthalmologists agree that long-term follow-up is valuable for pre-
term infants. However, the optimal follow-up period remains a matter of debate. 
After ROP treatment, individualized follow-up has been suggested. In severe cases 
life-long follow-up may be warranted due to the increased risk of late sequelae such 
as retinal detachment34-36. For infants that not have been treated for ROP, some au-
thors propose performing a first follow-up when the child is 2.5 years of age, while 
others claim that a follow-up at 4–5 years of age is sufficient to detect ophthalmo-
logical problems27,37. Most authors agree that special attention should be paid to 
infants with neurological complications. 
Screening for severe retinopathy of prematurity 
In most cases, blindness caused by ROP is preventable. It is therefore crucial to 
identify infants who are at risk of ROP. GA and birth weight (BW) are well-known 
major risk factors for ROP that reflect the infants’ degree of immaturity38,39. In 1988, 
the first ROP screening guidelines were presented in the study “Multicentre trial of 
cryotherapy for retinopathy of prematurity”40. These guidelines recommended that 
preterm infants with a BW <1251 g undergo ROP screening. In subsequent decades, 
these guidelines were adapted to the changing characteristics of the premature pop-
ulation, since advances in medicine led to higher survival of infants at lower GA, 
and more mature infants in high-income settings are less affected by ROP3. How-
ever, larger and more mature infants in low-income and middle-income settings can 
still develop ROP and require treatment; hence, ROP screening guidelines have to 
be adapted to the reality of quality of local medical care23.
Most of the commonly used ROP screening guidelines are based on GA and/or BW. 
Currently, in Sweden as in comparable high-income settings/countries, infants born 
at GA <31 weeks are screened for ROP. ROP screening starts at 5 weeks of age but 
should be conducted no earlier than at a postmenstrual age (PMA) 31 weeks (Figure 
4).
The ROP eye examination is usually initially performed weekly or biweekly until 
the retina is fully vascularized, which is usually at ~40 weeks PMA. If ROP is de-
tected, the frequency of eye examinations is determined on an individualized basis. 
An extremely preterm infant that develops severe ROP may undergo up to 30 eye 
examinations until the ROP is resolved41. 
The eye examinations themselves can be stressful as well as painful for the fragile 
preterm infant42. Elevated blood pressure, an increased need for oxygen supplemen-
tation, and increased heart rate are general signs of distress that are seen during or/
and after ROP screening examinations43-45.
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Figure 4. Mio is four weeks old, and soon it will be time for his first ROP screening ex-
amination. ©Stina Fahlén
Several interventions during the eye examination can have adverse effects on the 
infant. The eye examination is performed through dilated pupils, and the mydriatic 
drops that are given before the examination can cause oxygen saturation problems 
and gastrointestinal side effects45,46. Manipulation of the eye during the examination 
may also cause distress when the ophthalmologist inserts an eyelid speculum or uses 
cotton-tipped applicators, or fingers to separate the eyelids (Figure 5)43.
Figure 5. The retinopathy of prematurity (ROP) screening examination. ©Ann Hellström.
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The administration of sucrose, a pacifier, and local anesthetics during the ROP ex-
amination can reduce the infant’s distress and enhance recovery after ROP screen-
ing47,48.
The need for ROP screening is determined according to WHO’s established screen-
ing criteria49. The disease is well-defined, the natural course of the disease is rela-
tively well-known, and there are facilities available for diagnosis and treatment that 
are acceptable to the population being screened. However, improving the specificity 
of ROP screening of preterm infants is desirable since ~90–95% of infants screened 
for ROP do not develop ROP that requires treatment.
Risk factors for retinopathy of prematurity 
Many risk factors besides GA and BW have been identified since ROP was first 
described in Boston, Massachusetts (USA) in 1942 by T. Terry50. ROP is a multifac-
torial disease and additional risk factors may be: oxygen supplementation, multiple 
births, race, gender, prolonged mechanical ventilation, blood transfusion, steroids, 
hyperglycemia, renal insufficiency, sepsis, poor postnatal weight gain, poor nutri-
tional intake, growth factors, bronchopulmonary dysplasia (BPD), necrotizing en-
terocolitis (NEC), patent ductus arteriosus (PDA) and intaventricular hemorrhage 
(IVH) (Figure 6)51-64. 
Figure 6. Retinopathy of prematurity (ROP) is a multifactorial disease.
Oxygen supplementation 
Unrestricted oxygen supplementation has been a known risk factor for ROP since 
the 1950s64. However, guidelines concerning optimal oxygen saturation have not 
been definitively determined. Furthermore, optimal saturation targets seem to vary 
in different phases of ROP. In phase I (the first weeks of life), low oxygen saturation 
decreases the risk of severe ROP. In contrast, in phase II (after ~31 weeks PMA), 
high oxygen saturation seems to decrease the risk63,65. Moreover, introducing lower 
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oxygen saturation targets might be problematic since increased mortality rates in 
preterm infants have been associated with lower saturation targets66. The need for 
respiratory support, as quantified by the number of days on mechanical ventilation, 
has also been found to be a risk factor for severe ROP6,67,68.
Prenatal and neonatal infection and inflammation
It has been suggested that peri- and postnatal infections that elicit an inflammatory 
response in the preterm infant can predispose the retina to severe ROP69. One hy-
pothesis is that circulating inflammatory cytokines affect the retina. Cytokines have 
the ability to modulate angiogenesis: they can have both anti- and pro-angiogenic 
activity as well as both anti- and pro-inflammatory activity. Coordinated temporal 
and spatial cytokine expression appears to be necessary and important for normal 
development of the retina70.
Prenatal infection, e.g. chorioamnionitis and elevation/dysregulation of inflamma-
tion-related proteins such as cytokines, is associated with preterm birth as well as 
with postnatal morbidities such as IVH, BPD, NEC, and ROP70-73. Neo- and post-
natal sepsis, candida sepsis, and general sepsis also increase the risk of ROP74-76.
Gender
When ROP was first recognized in the 1940s, male infants were reported to be more 
frequently affected by the disease77. Some subsequent studies have confirmed these 
results61,62,78. It is not known how gender affects the development of ROP, but male 
fetuses have generally been found to be more vulnerable than female fetuses. Male 
gender is associated with an increased risk of preterm birth and neonatal mortality 
and morbidity79. In particular, male infants who are born extremely preterm have an 
increased risk of visual impairment compared to female infants80.
Growth restriction at birth
Whether growth restriction at birth is a risk factor for severe ROP remains contro-
versial. In some studies, growth restriction at birth was found to be a risk factor for 
ROP78,81-83, while other studies found no such pattern6,59,84,85. There is no consensus 
regarding the definition of growth restriction or the reference standard that should 
be used when calculating growth restriction.
Definitions of growth restriction at birth
As an estimation of whether an infant is growth restricted at birth, infants are com-
monly classified as “small for gestational age” (SGA) or “appropriate for gestational 
age”. In Sweden, SGA is usually defined as BW, relative to GA and according to 
gender, that is 2.0 standard deviation scores (SDS) below normal. Another defini-
tion of SGA is BW below the 10th percentile, which approximately corresponds to 2 
SDS below the relative GA mean. The term “severe growth restriction” is also used 
in some studies and is commonly defined as BW below the 3rd percentile.
Growth restriction at birth can also be described as divergence in birth weight stan-
dard deviation score (BWSDS), which allows for a continuum description of growth 
restriction. 
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terocolitis (NEC), patent ductus arteriosus (PDA) and intaventricular hemorrhage 
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Figure 6. Retinopathy of prematurity (ROP) is a multifactorial disease.
Oxygen supplementation 
Unrestricted oxygen supplementation has been a known risk factor for ROP since 
the 1950s64. However, guidelines concerning optimal oxygen saturation have not 
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in different phases of ROP. In phase I (the first weeks of life), low oxygen saturation 
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high oxygen saturation seems to decrease the risk63,65. Moreover, introducing lower 
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oxygen saturation targets might be problematic since increased mortality rates in 
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and spatial cytokine expression appears to be necessary and important for normal 
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natal sepsis, candida sepsis, and general sepsis also increase the risk of ROP74-76.
Gender
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Definitions of growth restriction at birth
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age”. In Sweden, SGA is usually defined as BW, relative to GA and according to 
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in some studies and is commonly defined as BW below the 3rd percentile.
Growth restriction at birth can also be described as divergence in birth weight stan-
dard deviation score (BWSDS), which allows for a continuum description of growth 
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Growth charts
Different growth charts are used in different places around the world to estimate a 
preterm infant’s growth deficit at birth and to estimate an infant’s postnatal growth. 
Some growth charts aim to describe undisturbed intrauterine growth and are based 
on longitudinal fetal ultrasound weight estimates86,87. Other growth charts are based 
on live and still births,88 and others are based on live birth preterm infants89,90. The 
use of different growth charts leads to inconsistencies in the descriptions of infant 
characteristics in different study cohorts. Using growth charts that are based on live 
and still births, such as Kramer’s growth chart,88 minimizes the birth weight deficit 
of the infants in the study population, while using a growth chart based on fetal 
ultrasound, such as Marsal’s growth chart,86 emphasizes the birth weight deficits 
of preterm infants. After birth, neonatal care generally aims to mimic intrauterine 
growth91. 
Poor postnatal growth
In 1956, Hellström et al. reported a correlation between poor postnatal weight gain, 
nutritional status, and the development of retinal neovascularization in oxygen-ex-
posed mouse pups92. Poor postnatal weight gain emerged as a risk factor for severe 
ROP in preterm infants around the beginning of the new millennium. Both Wal-
lace et al. and Fortes Filho et al. have reported that weight gain measured at 6 weeks 
after birth could be used as a predictor for severe ROP93,94. Several other studies 
confirmed these results. Thus adequate weight gain during the first weeks of life 
may prevent the development of ROP, a disease that appears several weeks later 
(Figure 7)67,94-96.
Figure 7. Longitudinal mean weight standard deviation (WSDS) from the historical 
norm at birth for 131 Swedish infants from week 23 to 40 GA for infants with no ROP 
(stage 0) (n=68), mild ROP (stages 1 and 2) (n=40) and proliferative ROP (stage 3 
and above) (n=23)97,98. (Adapted from A Hellström, New insights into the development 
of retinopathy of prematurity – importance of early weight gain. Acta Paediatr. 2010 
Apr;99(4):502-8. By permission of Wiley production.)
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Estimating growth in preterm infants
The growth of preterm infants is generally assessed by measuring the infant’s weight, 
length, and head circumference (Figure 8). 
Figure 8. Flexible measuring tape inside an incubator. ©Elisabeth Stoltz Sjöström
Although measuring infant length and head circumference can be challenging in 
a preterm infant, weight measurements are usually preformed routinely—either 
weekly or daily at the neonatal ward—as an indicator of overall growth.
In term infants, weight loss after birth that is less than 10% of the BW is considered 
the normal consequence of post-birth changes in cellular fluid compartments99. The 
time at which the infant weighs the least, termed the nadir, usually occurs at postna-
tal day 3 in term infants. Term infants often regain their BW by postnatal day 5–10. 
However, postnatal growth deficit is a common problem in preterm infants100, who 
often show greater and more prolonged initial postnatal weight loss101.
If his or her course is favorable, a preterm infant is hospitalized until PMA ~36–
38 weeks. At discharge, most preterm infants have not achieved the median birth 
weight of a reference fetus of the same PMA102. In the Extremely Preterm Infants in 
Sweden Study (EXPRESS) cohort, which included infants born at GA <27 weeks in 
Sweden during 2004–2007, 16% of the infants were classified as growth restricted at 
birth (BW <-2.0 SDS), while at the time of discharge at PMA 36 weeks, the percent 
of infants defined as growth restricted had increased to 44%6.
When estimating infant growth using weight measurements, the physician needs to 
assess whether the infant’s weight reflects their overall growth. This is because the 
measured weight can be a false indicator of satisfactory postnatal growth. Excessive 
edema, hydrocephalus, and medical equipment attached to the infant can cause 
non-physiological weight gain that does not reflect actual growth. 
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Low levels of growth factor IGF-I 
Low levels of postnatal IGF-I have been associated with the development of severe 
ROP and poor postnatal weight gain51,96,103. From GA ~29 weeks, the serum levels 
of IGF-I in the fetus increase two- to three-fold. Fetal IGF-I levels correlate with 
both fetal size and GA104. After the maternal-fetal interaction is interrupted by birth, 
postnatal levels of IGF-I in the newborn infant decrease considerably105. While term 
infants restore their IGF-I levels within the first few postnatal weeks, preterm in-
fants are poorly equipped to maintain the in-utero IGF-I levels106. IGF-I is mainly 
synthesized in the liver, and serum levels reflect the multifactorial influences of, for 
example, nutritional status, infection status, and endocrine conditions107.
Low postnatal levels of IGF-I in preterm infants have been associated with overall 
growth deficiency and with vascular growth retardation108. IGF-I mediates VEGF 
vessel growth109; consequently, IGF-I is considered an important actor in phase I and 
phase II of ROP.
Poor nutritional intake
Poor nutritional intake during the first weeks of life was identified recently as a risk 
factor for severe ROP. VanderVeen at al. demonstrated that infants with the lowest 
total energy intake during the first four weeks of life have an increased risk of severe 
ROP52. Increased protein and energy intake during the first weeks of life are also as-
sociated with a favorable neurodevelopmental outcome in preterm infants110.
Optimizing nutritional intake
Nutritional deficits and poor postnatal growth are major problems in preterm in-
fants111,112. The metabolic rates of preterm infants are higher than in age-matched 
fetuses and, consequently, their nutrient and energy requirements are extremely 
high113. Evidence-based recommendations for preterm infants in terms of energy 
requirements remain largely incomplete, and the standard goal of mimicking intra-
uterine growth is difficult to accomplish. Furthermore, in the intrauterine environ-
ment, the placenta, amnion, and amniotic fluids provide the fetus not only with 
nutrients, but also with growth factors such as IGF-I, hormones, and probably other 
as-yet unidentified factors. It has been suggested that ~45% of the variation in post-
natal growth is related to energy intake112.
During the first weeks of a preterm infant’s life, nutrients are usually supplied by 
parenteral as well as enteral routes in an attempt to optimize the nutritional supply 
(Figure 9).
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Figure 9. Mio is growing satisfactory; he is now 6 weeks old. ©Stina Fahlén 
It is recommended that enteral feeding should be started as soon as possible after 
birth, and human milk is the preferable standard enteral source114. Early intake of 
human milk stimulates the maturation of the intestinal system and reduces the risk 
of NEC115,116. Nutritional intake is usually calculated from parenteral and enteral 
sources as intake of energy (kcal/kg/d) and as intake of macronutrients (protein, fat, 
and carbohydrates expressed as g/kg/d). The estimated requirements for energy in-
take differs depending on whether parenteral or enteral sources are used, recommen-
dations for energy intake for growing, extremely preterm infants (after the first five 
days of life) are as follows: 110–130 kcal/kg/d117 for enteral nutrition and 105–115 
kcal/kg/d118 or 110–120 kcal/kg/d119 for parenteral nutrition. However, adequate nu-
tritional intake are seldom achieved in extremely preterm infants120.
Omega-3 long-chain polyunsaturated fatty acids 
Fatty acids, especially docosa hexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA) that are omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), are es-
sential for the development of neurons and blood vessels in the brain and retina121.
During the third trimester, there is a major selective transfer of LCPUFAs from the 
mother to the fetus concomitant with the rapid development of neurons in the brain 
and the retina122,123. When they are born preterm, infants lose this essential trans-
mission of LCPUFAs, and the preterm infants are unable to synthesize enough of 
these fatty acids themselves124. Thus it is crucial that lipid supplementation is begun 
during the preterm infant’s first days of life. An early lipid supply is associated with 
improved neurological outcome125.
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Animal studies have indicated that the quality of the fatty acids may be important 
in ROP development. A lipid diet that is rich in omega-3 LCPUFAs, e.g. DHA and 
EPA, reduces the risk of ROP in mouse pups and in humans126,127.
The parental nutrition that is most commonly used today contains mainly omega-6 
LCPUFAs and almost no omega-3 LCPUFAs. Pawlik et al. reported the beneficial 
effects of omega-3 LCPUFAs on ROP and those results are supported by data from 
an ongoing study in Sweden (EUCTR2008-000046-31-SE). Specifically, the pre-
liminary data suggest a substantial reduction of severe ROP in infants that were 
given fortified omega-3 supplementation, and these results are in agreement with 
similar studies.127.
Preterm morbidities associated with retinopathy of prematurity
Several comorbidities that affect the preterm infant have been found to correlate 
with ROP, such as BPD, NEC, PDA and IVH55-57.
Bronchopulmonary dysplasia 
BPD is characterized by distal lung growth and maturation failure, such as impaired 
alveolarization and impaired vascular growth128. The disease is considered to have 
a multifactorial etiology that involves both oxygen toxicity and pre- and postnatal 
inflammation processes129,130. BPD is commonly defined as the need for supplemen-
tal oxygen 28 days after birth or at PMA 36 weeks; this need reflects the severity of 
the disease131. Systemic corticosteroids are currently the most common treatment for 
BPD, although this is controversial since systemic corticosteroids increase mortality 
in preterm infants and have a negative effect on early growth and neurodevelop-
ment131. 
Necrotizing enterocolitis 
NEC involves inflammation and a bacterial invasion of the bowel walls that usu-
ally occurs within the first weeks of life. Like BPD, NEC also has a multifactorial 
etiology. The symptoms of NEC include both abdominal and nonspecific systemic 
signs. The abdominal signs may include a distended abdomen, an absence of bowel 
sounds, and blood in the stool. The systemic signs of NEC can include increased 
apnea, bradycardia, irritability, and lethargy132. In the worst-case scenario, NEC can 
cause bowel necrosis. NEC is a severe morbidity and one of the leading causes of 
mortality in preterm infants. Approximately 20–30% of infants with NEC die de-
spite treatment133. The treatment depends on the stage of the disease; in mild cases, 
nasogastric decompression, parenteral feeding, and broad-spectrum antibiotics are 
recommended, while in severe cases of NEC, surgical intervention is warranted. 
Infants who survive NEC have additional gastrointestinal complications as well as 
an increased risk of neurological impairment134.
Patent ductus arteriosus 
PDA is a condition in which the fetal ductus arteriosus vessel, which connects the 
main pulmonary artery to the descending aorta, does not close after birth (it usually 
closes within the first 24–28 hours in infants born at term). PDA is most frequently 
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found in the most immature infants and it can cause circulatory and saturation fail-
ure6,135. It can be treated effectively either by surgical closure or by pharmacological 
treatment, depending on the local guidelines.
Intraventricular hemorrhage 
The etiology of IVH in neonates is multifactorial but is considered to be caused 
primarily by instabilities in cerebral blood flow136. IVH usually manifests within the 
first 72 hours of life, and extremely preterm infants are the most affected137. Their 
immature brains are especially sensitive to changes in cerebral perfusion, hypoxia, 
and oxidative stress, leading to cell death and bleeding138. IVH is classified as grade 
1 to 4, with IVH grades 3–4 considered severe IVH139. In preterm infants, severe 
IVH impacts mortality rates and short- and long-term morbidity. Hydrocephalus, 
cerebral palsy, and neurodevelopment disabilities have been reported in affected in-
fants140. Currently there is no way of stopping the bleeding associated with IVH. If 
the bleeding causes hydrocephalus a ventriculoperitoneal shunt may be warranted141.
Novel Approaches to predicting severe retinopathy of pre-
maturity 
Most ROP screening guidelines are based on GA and/or BW and do not take into 
account postnatal risk factors for severe ROP. Established ROP screening guidelines 
result in repeated examinations of very fragile infants. Notably, 90–95% of these in-
fants will never need treatment for ROP, and the examinations are both painful and 
stressful. To reduce the burden of these examinations on the infants, identification 
of those most at risk for sight-threatening ROP must be improved.
Biomarkers as predictors for retinopathy of prematurity
Biomarkers are measurable indicators of some biological state or condition. Biomark-
ers are often isolated from serum, urine, or other fluids whose detection indicates the 
presence or severity of a particular disease. Some biomarkers have been correlated 
with ROP. For example, biomarkers in circulation associated with oxidative stress, 
inflammation, glucoses metabolism and also growth factors103,109,142-146. However, the 
value of these biomarkers is yet to be defined as they have not been validated in 
clinical practice. Postnatal weight measurement is so far the only biomarker that has 
been found to be applicable in ROP screening models.
WINROP
The finding that low levels of serum IGF-I and poor postnatal weight gain correlate 
with ROP prompted the development of a web-based surveillance system for pre-
dicting severe ROP. This algorithm is termed WINROP, which stands for Weight, 
IGF-I, Neonatal, Retinopathy Of Prematurity. WINROP was developed based on a 
study of Swedish preterm infants, which was later validated, that reported that post-
natal serum levels of IGF-I and weekly weight measurements could predict whether 
an infant was at high risk of developing severe ROP that required treatment51,97. Af-
ter further development of the WINROP algorithm, weekly weight measurements 
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without IGF-I measurement were found to be equally valuable for making these pre-
dictions. Accordingly, serum IGF-I measurement was removed from WINROP96. 
By recording the infant’s BW and GA along with weekly weight measurements, 
WINROP accumulates and calculates the infant’s risk of developing severe ROP 
that requires treatment. The WINROP system has an alarm function that signals if 
an infant is at high risk of developing ROP requiring treatment. Even if WINROP 
does not give this signal, weekly weight measurements must be performed until the 
infant is at PMA 35–36 weeks. Not until then can the infant be completely free of 
risk as evaluated by WINROP.
WINROP has been validated in several Swedish cohorts as well as in cohorts in oth-
er countries such as the United States, Mexico, Brazil, China, Korea, and the United 
Kingdom98,147-152. The largest study to date included 1700 infants in a multicenter 
cohort in North America. The sensitivity and specificity of WINROP varies slightly 
between the cohorts; this is proposed to be due to the characteristics of the infants 
that are born preterm. Notably, the characteristics of the preterm population can 
differ in different countries/hospitals according to the quality of pre- and neonatal 
care. It has been suggested that WINROP could be more useful if it was adapted to 
the characteristics of different populations148.
WINROP is meant to be a supplement rather than a substitute to established ROP 
screening practices. The aim of WINROP is to safely minimize the number of ROP 
screening examinations in infants at low risk of ROP requiring treatment and to 
alert physicians to pay special attention to infants who are at high risk.
To our knowledge, WINROP (www.winrop.com) is the first and only validated 
web-based surveillance system that estimates the preterm infant’s risk of developing 
ROP requiring treatment.
ROP score
The “ROP score” of Eckert et al. involves recording BW, GA, blood transfusion 
data, and oxygen therapy data in the first 6 weeks of life and weight at 6 weeks of 
life in an Excel sheet that calculates a ROP score. Cut-off points based on the ROP 
score then predict the infant’s risk of developing any ROP and severe ROP. In a 
Brazilian cohort (n=474) the ROP score was found to have a sensitivity of 98% and 
a specificity of 56%153.
CHOP ROP score
Another new model to predict ROP type 1 is the Children’s Hospital of Philadelphia 
(CHOP) ROP model proposed by Binenbaum et al.154. In the CHOP ROP model, 
BW, GA and mean daily weight gain data is calculated on a weekly basis. A normo-
gram or a hand calculator is required to use the CHOP ROP model. The CHOP 
ROP model was found to have a sensitivity of 98% and a specificity of 53% in a 
cohort from Philadelphia (USA) (n=524).
CRIB score
The Clinical risk index for babies (CRIB) score estimates illness severity during 
the first 12 hours after birth by 6 variables: BW, GA, congenital malformation, 
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maximum base excess and maximum and minimum appropriate FiO2 (fraction of 
inspired oxygen)155. Yang et al. investigated high CRIB score in correlation to ROP 
warranting treatment. They found that a high CRIB score was an independently 
significant predictor for ROP warranting treatment as well as in combination with 
male gender and nonblack race when GA and BW were excluded61.
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Aim
General aim and hypothesis
The general aim of the studies performed in my thesis was to evaluate growth and 
nutrition variables as predictors of severe ROP in preterm infants. The primary focus 
has been to further investigate whether the peri- and postnatal weight deficit is a 
robust and useful predictor for severe ROP.
The specific aims were as follows:
•	 To validate the WINROP algorithm in an extremely preterm nation-based 
cohort (Paper I).
•	 To investigate if the infant’s weight at first detection of ROP correlated with the 
risk of developing severe ROP (Paper II).
•	 To investigate birth weight deficit as a risk factor for severe ROP (Paper III).
•	 To evaluate the effects of energy and macronutrient intake during the first weeks 
of life on the risk for severe ROP (Paper IV).
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Study populations
Papers I, III, and IV studied the EXPRESS cohort (Paper III studied additional 
cohorts as well; see below). EXPRESS is a retrospective nation-based study that in-
cluded all infants born at GA <27 weeks in Sweden between 2004 and 2007 (n=707 
live births)4.
Paper II studied infants born at GA< 32 weeks in the Gothenburg region in 2011–
2012. All infants were born and were screened for ROP at the Sahlgrenska Univer-
sity Hospital (n=194).
Paper III included infants from five WINROP studies that were performed pre-
viously. The cohorts were from the following studies: EXPRESS (n=426), North 
America (n=1772)150, Boston (n=338)151, Lund (n=52)98, and Gothenburg (n=353)96. 
All infants were born at GA <32 weeks, and all were screened for ROP.
Data collection
Birth characteristics
The infants’ BW, GA, and gender data were retrieved retrospectively from hospital 
records in all studies. For infants in the EXPRESS cohort, data related to neonatal 
morbidity, such as days of mechanical ventilation, PDA, IVH, antibiotic treatment, 
and steroid treatment, as well as the CRIB score, were retrieved from the original 
EXPRESS studies4,6.
Weekly weight measurements
Weekly weight measurements were retrospectively retrieved from hospital records or 
after discharge from records at the local children’s healthcare center. Since WIN-
ROP needs weekly weight measurement data for each PMA week, the aim was to re-
trieve one weight measurement each PMA week and, preferably, to have a seven-day 
interval between measurements. Weekly weight measurements were retrieved for all 
infants until PMA 32–40 weeks, depending on the study design.
ROP screening 
ROP screening was performed in all cohorts according to the then current national 
guidelines and consisted of dilated ocular fundus examinations. All infants were 
examined until complete retinal vascularization or until spontaneous or post-treat-
ment regression of ROP. The revised International Classification of Retinopathy of 
Prematurity was used for classifying ROP, and the recommendations of the Early 
Treatment for Retinopathy of Prematurity Cooperative Group were followed for 
ROP treatment15,34. Depending on the study design, the following ROP variables 
were retrieved: the number of ROP eye examinations, the date at which ROP was 
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first detected, the maximal ROP stage, the affected zone in each eye, and ROP treat-
ment, if required, including the date(s) of treatment.
Nutritional data
Nutritional data for the EXPRESS cohort were mainly obtained retrospectively 
from hospital records by a registered dietitian (the first author of Paper IV). Com-
prehensive enteral and parenteral nutritional intake data were retrieved daily for 
the first 28 postnatal days; thereafter, we obtained data for one day per week (i.e. 
for days 35, 42, etc.) until data were no longer available. Nutritional intake was as-
sessed as energy (kcal/kg/d) and as macronutrients (protein, fat, and carbohydrates 
expressed as g/kg/d). Enteral nutritional sources included the mother’s milk, donor 
human milk, and various formula and human milk fortifiers. Later on, supplements 
such as vitamins and minerals were also defined as enteral sources. Parenteral nu-
tritional sources included various nutritional preparations that contained glucose, 
amino acids, and lipids. Intravenous fluids such as blood products, drug infusions, 
and flush solutions were also included.
Exclusions
Infants were excluded if the infant died before ROP screening was completed e.g. 
before a PMA of 40 weeks. Infants with incomplete weight data, mainly incomplete 
weekly weight measurements, were excluded, as were infants in whom the weight 
measurements were judged to inaccurately reflect physiological postnatal weight 
gain (e.g. when the weight also reflected accumulated fluid, as in hydrocephalus). In 
Paper IV, infants with missing nutritional data were excluded. For detailed informa-
tion regarding excluded infants please see Papers I-IV.
Statistics
In summary, normally distributed data were presented as means and 95% confi-
dence intervals (CIs), and data that were not normally distributed were presented as 
medians and ranges. Odds ratios (ORs) with 95% CIs were calculated for each risk 
factor in logistic regression analyses. The Hosmer-Lemeshow goodness-of-fit test was 
used to check the fit for logistic regression models. In logistic regression analysis, the 
OR and 95% CI were calculated for each risk factor, and the level of significance of 
a risk factor was set as p value <0.05.
Paper I: The sensitivity, specificity, and positive and negative predictive values were 
calculated using Vassar Stats (www.vassarstats.net). The outcome variable was ROP 
type 1 requiring treatment.
Paper II: BWSDS and WSDS were calculated with a Swedish gender-specific refer-
ence86. The Mann-Whitney U test was used for calculating differences in the medi-
ans of variables at first detection of ROP. Univariate and multivariate logistic regres-
sion analysis was used to evaluate risk factors. Pearson’s correlation coefficient was 
used to estimate correlations between risk factors. Receiver operating characteristic 
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(ROC) curve and area under the curve (AUC) analysis were performed to estimate 
the predictive capacity of the models. The outcome variable was ROP requiring 
treatment.
Paper III: BWSDS was calculated using a Swedish gender-specific reference as well 
as using a Canadian gender-specific reference86,88. Using the Swedish growth refer-
ence, SGA was defined as BW <-2.0 BWSDS; using the Canadian growth reference, 
SGA was defined as BW <10th percentile. Severe growth restricition was defined as 
BW <3rd percentile using the Canadian growth reference. The Wilcoxon signed-
rank test was used to compare the two BWSDS references. The Mann-Whitney U 
test was used for group comparisons. Correlations were assessed using the Spearman 
correlation coefficient (rs). By designing an interaction term (BWSDS*GA group), 
we assessed whether BWSDS had a different impact as a risk factor depending on 
the infant’s GA at birth (GA group 0 if GA <26 weeks and GA group 1 if GA ≥26 
weeks). Univariate and multivariate logistic regression analysis were used to evaluate 
risk factors. The outcome variable was ROP requiring treatment.
In Papers II and III, the data were analyzed using IBM SPSS Statistical software for 
Windows, version 20.0 (Armonk, NY, USA, IBM Corp) and SAS version 9.3 (Cary, 
North Carolina, USA).
Paper IV: BWSDS and WSDS were calculated using a Swedish gender-specific ref-
erence87. Univariate and multivariate logistic regression analysis were used to evalu-
ate risk factors. A categorical hospital variable was included in the final analysis. The 
outcome variable was severe ROP defined as ROP stages 3–5.
In Paper IV, the data were analyzed using IBM SPSS Statistical software for Win-
dows, version 20.1 (Chicago, IL, USA, IMB Corp) and R (version 3.01).
Ethical considerations 
The studies in this thesis were carried out in compliance with the ethical principles 
for medical research involving human subjects outlined in the Declaration of Hel-
sinki.
The Regional Ethical Review Board in Gothenburg, Sweden approved the studies in 
Papers I, II, and III (Dnr 504-09).
In Paper III, the North American studies were approved by the institutional review 
boards at all participating centers.
The Regional Ethical Review Board in Lund, Sweden (Dnr 138-2008) approved 
Papers I and IV.
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Results
This thesis comprises four papers that evaluated risk factors that could be used to 
optimize ROP screening (Figure 10). 
Figure 10. An overview of the main aims and results of the four studies in this thesis 
(Papers I–IV) and the additional results that are included in this thesis.
Infants’ birth characteristics
In this thesis, a total of 3088 preterm infants were included from six study cohorts. 
The birth characteristics of the infants in the different study cohorts are presented in 
Table 1. The birth characteristics of the EXPRESS cohort are presented as in Paper 
III. There were minor differences in the characteristics of the EXPRESS cohort in-
cluded in Papers I (Table 1) and IV due to differences in study design.
Table 1. The birth characteristics of the preterm study infants.
Cohort Infants,
n
GA,
weeks+days
BW, grams BWSDS* Male 
gender 
EXPRESS
(Paper III)
426 25+4/7
(22+1/7 to 26+6/7)
780
(361–1315)
-0.68
(-5.18 to 3.88)
54.0%
Gothenburg
(Paper II)
147 29+1/7
(22+6/7 to 31+6/7)
1185
(440–2840)
-1.04
(-4.55 to 5.20)
51.7%
North American
(Paper III)
1772 28+0/7
(22+5/7 to 31+6/7)
1010
(378–2240)
-1.34
(-6.62 to 3.35)
52.5%
Boston
(Paper III)
338 28+5/7
(23+1/7 to 31+6/7)
1050
(450–2400)
-1.31
(-5.18 to 4.47)
54.7%
Lund
(Paper III)
52 26+1/7
(23+0/7 to 30+5/7)
850
(448–1716)
-0.77
(-5.00 to 0.89)
51.9%
Gothenburg
(Paper III)
353 29+4/7
(23+3/7 to 31+6/7)
1290
(425–2210)
-1.04
(-5.59 to 2.50)
59.2%
Values are reported as median (range) as appropriate
*Swedish reference (Marsal K, 1996)86
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Frequency of retinopathy of prematurity
The frequency of ROP varied as expected according to GA, with the most immature 
infants having the highest risk of developing any ROP and severe ROP. The fre-
quency of ROP according to GA is presented in Table 2, which shows data from all 
infants included in the studies in this thesis (n=3088). 
Table 2. The frequency of retinopathy of prematurity (ROP) and ROP treatment in 
preterm infants in the study cohorts.
GA, weeks No ROP ROP stages 1–2
(mild ROP)
ROP stages 3–5
(severe ROP)
ROP 
treatment
22 w (n=6) ─ 16.7% 83.3% 83.3%
23 w (n=125) 6.4% 36.8% 56.8% 45.6%
24 w (n=304) 5.9% 42.5% 51.6% 34.5%
25 w (n=407) 17.0% 53.3% 29.7% 18.4%
26 w (n=445) 33.5% 49.7% 16.8% 8.3%
27 w (n=294) 40.5% 49.7% 9.8% 7.1%
28 w (n=364) 62.1% 34.3% 3.6% 1.4%
29 w (n=374) 72.8% 25.9% 1.3% 1.1%
30 w (n=428) 89.7% 9.6% 0.7% 0.2%
31 w (n=341) 93.8% 6.2% ─ ─
Total (n=3088) 50.7% 33.8% 15.5% 10.0%
The most immature infants constitute a small part of the population of infants 
screened for ROP, although a large proportion of them develop severe ROP. Figure 
11 show the ROP frequency in preterm infants as percentages. 
Figure 11. A. The percentage of preterm infants according to ROP development (n=2662). 
The EXPRESS cohort was excluded from this analysis. B. The percentage of preterm in-
fants according to ROP development in the EXPRESS cohort (n=426).
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Figure 12 shows the number of infants with ROP according to GA.
Figure 12. The number of infants born at GA <26 weeks and GA ≥26 weeks in relation 
to ROP development (n=2662). The EXPRESS cohort was excluded from this analysis.
Validation of WINROP in the EXPRESS cohort
In the EXPRESS cohort, we found that the sensitivity of WINROP for predicting 
ROP type 1 was high, 95.7%, but the specificity was low, 23.9%. WINROP signaled 
an alarm in 319 (78%) of the extremely preterm infants; however, only 47 (12%) of 
the infants in the cohort developed ROP type 1 requiring treatment (Table 2, Paper 
I). In addition to the 47 infants that developed ROP type 1, an additional 19 infants 
who did not fulfill established treatment criteria received treatment (Table 1, Paper 
I). Two infants had ROP type 1 that was not predicted by WINROP; both were 
born at GA 25 weeks and had a severe clinical postnatal course (Table 3, Paper I).
WINROP signaled early with an alarm at a median of 3 weeks after birth. The 
alarm was signaled several weeks to months before treatment, with signals a median 
of 9 weeks before the first treatment. The median PMA for receiving the first treat-
ment was 36 weeks in the EXPRESS cohort (Figure 3, Paper I). In the EXPRESS 
cohort, a mean of 11 eye examinations were performed per infant (Paper I).
Reassessment of the WINROP alarm
With the intention of improving the specificity of WINROP for extremely preterm 
infants, we retrospectively analyzed the infants’ weight at the time of WINROP 
alarm. Our analysis included the EXPRESS cohort (n=407) as well as GA-matched 
extremely preterm infants from the North American cohort (n=566). We analyzed 
the weight at time of the WINROP alarm in relation to GA at birth and PMA at 
alarm. Many of the extremely preterm infants had poor postnatal weight develop-
ment; thus, many had a WINROP alarm. However, we were able to establish a 
“safe” alarm weight. If the infant had gained enough weight at the time of the alarm, 
the infant did not develop ROP type 1. Infants born at GA 26 weeks had a lower 
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(severe ROP)
ROP 
treatment
22 w (n=6) ─ 16.7% 83.3% 83.3%
23 w (n=125) 6.4% 36.8% 56.8% 45.6%
24 w (n=304) 5.9% 42.5% 51.6% 34.5%
25 w (n=407) 17.0% 53.3% 29.7% 18.4%
26 w (n=445) 33.5% 49.7% 16.8% 8.3%
27 w (n=294) 40.5% 49.7% 9.8% 7.1%
28 w (n=364) 62.1% 34.3% 3.6% 1.4%
29 w (n=374) 72.8% 25.9% 1.3% 1.1%
30 w (n=428) 89.7% 9.6% 0.7% 0.2%
31 w (n=341) 93.8% 6.2% ─ ─
Total (n=3088) 50.7% 33.8% 15.5% 10.0%
The most immature infants constitute a small part of the population of infants 
screened for ROP, although a large proportion of them develop severe ROP. Figure 
11 show the ROP frequency in preterm infants as percentages. 
Figure 11. A. The percentage of preterm infants according to ROP development (n=2662). 
The EXPRESS cohort was excluded from this analysis. B. The percentage of preterm in-
fants according to ROP development in the EXPRESS cohort (n=426).
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Figure 12 shows the number of infants with ROP according to GA.
Figure 12. The number of infants born at GA <26 weeks and GA ≥26 weeks in relation 
to ROP development (n=2662). The EXPRESS cohort was excluded from this analysis.
Validation of WINROP in the EXPRESS cohort
In the EXPRESS cohort, we found that the sensitivity of WINROP for predicting 
ROP type 1 was high, 95.7%, but the specificity was low, 23.9%. WINROP signaled 
an alarm in 319 (78%) of the extremely preterm infants; however, only 47 (12%) of 
the infants in the cohort developed ROP type 1 requiring treatment (Table 2, Paper 
I). In addition to the 47 infants that developed ROP type 1, an additional 19 infants 
who did not fulfill established treatment criteria received treatment (Table 1, Paper 
I). Two infants had ROP type 1 that was not predicted by WINROP; both were 
born at GA 25 weeks and had a severe clinical postnatal course (Table 3, Paper I).
WINROP signaled early with an alarm at a median of 3 weeks after birth. The 
alarm was signaled several weeks to months before treatment, with signals a median 
of 9 weeks before the first treatment. The median PMA for receiving the first treat-
ment was 36 weeks in the EXPRESS cohort (Figure 3, Paper I). In the EXPRESS 
cohort, a mean of 11 eye examinations were performed per infant (Paper I).
Reassessment of the WINROP alarm
With the intention of improving the specificity of WINROP for extremely preterm 
infants, we retrospectively analyzed the infants’ weight at the time of WINROP 
alarm. Our analysis included the EXPRESS cohort (n=407) as well as GA-matched 
extremely preterm infants from the North American cohort (n=566). We analyzed 
the weight at time of the WINROP alarm in relation to GA at birth and PMA at 
alarm. Many of the extremely preterm infants had poor postnatal weight develop-
ment; thus, many had a WINROP alarm. However, we were able to establish a 
“safe” alarm weight. If the infant had gained enough weight at the time of the alarm, 
the infant did not develop ROP type 1. Infants born at GA 26 weeks had a lower 
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“safe” weight at the time of the alarm compared to infants born at GA of 23–25 
weeks, leading to two subgroups of “safe” alarm weight limits (Figure 13).
Figure 13. WINROP alarm weight cut-offs (n=973). Infants with an alarm weight in 
the “safe” zone did not require ROP treatment, while infants in the “unsafe” zone did.
Using the constructed alarm weight cut-offs, we performed an inter-sample reas-
sessment of the WINROP alarm in the same cohorts (i.e. the EXPRESS and North 
American cohorts). Infants with alarm weight below the cut-off value remained at 
risk, and infants with alarm weight above the cut-off were considered to have no 
alarm.
In the EXPRESS cohort, 12.5% of the infants that previously received a WINROP 
alarm were now reassessed as having no alarm. The specificity of WINROP in EX-
PRESS improved from 23.9% to 35.0%. In the North American cohort, 15.4% were 
reassessed as having no alarm, and the specificity increased from 8.5% to 26.6% . 
The sensitivity was not affected in either cohort (unpublished data).
The majority of infants who were born extremely preterm that could be reassessed 
as having no WINROP alarm were born at GA 26 weeks and had an early alarm 
(Figure 14).
Figure 14. The number of preterm infants reassessed as having no WINROP alarm ac-
cording to alarm week. The EXPRESS and North American cohorts were included in 
the analysis (n=973).
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Weight at first detection of retinopathy of prematurity as a 
risk factor
In Paper II, we found another possible weight cut-off for predicting ROP disease. 
Specifically, we found that the infants’ weight at the time of first detection of ROP 
could be used as a predictor for the progression of ROP.
In the Gothenburg cohort (n=147), we found that infants that were later treated for 
ROP had a lower median weight (1540 g vs. 1995 g; p<0.001) and lower median 
WSDS (-1.18 vs. -2.19; p<0.001) at the time of first detection of ROP compared to 
infants that were not treated (Table 1 and Figure 2, Paper II).
Figure 15.  Weight development in the weight standard deviation score (WSDS) in in-
fants who developed any ROP or who required ROP treatment. Diamonds represent the 
time at first detection of ROP. The error bars represent ± 1 SE.
When performing stepwise backward multivariate logistic regression analysis with 
the variables GA at birth, BW, PMA at first detection of ROP, weight at first detec-
tion of ROP, and WSDS at first detection of ROP, we found that the best combina-
tion of risk factors was GA and WSDS at first detection of ROP, which correctly 
classified 69% of infants requiring treatment. A received operator ROC curve that 
included GA at birth and WSDS at first detection of ROP showed an AUC of 0.93 
(Figure 3, Paper II).
In Paper II, we again found indications that weight cut-offs could be useful for 
predicting the need for ROP treatment. No infant with weight >2000 g or a WSDS 
above -1.13 SDS at first detection of ROP was later treated for ROP.
Birth weight as a risk factor
In Paper III, we analyzed BW relative to GA and gender as a risk factor for ROP 
treatment in 2941 infants. We found that depending on the infants’ GA, low BW 
could be a risk factor for ROP requiring treatment.
We calculated the BWSDS using two different growth references, a Canadian and a 
Swedish growth reference, for each GA group: GA 22–23 weeks, GA 24–25 weeks, 
GA 26–27 weeks, GA 28–29 weeks, and GA 30–31 weeks. We found significant 
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differences in the BWSDS values using the two growth references (Wilcoxon signed-
rank test, p<0.001) except in the group GA 22–23 weeks. With both growth refer-
ences, there was a negative correlation between BWSDS and GA at birth i.e. growth 
restriction at birth was more common in infants born after longer gestation (Figure 
16).
Figure 16. Mean (SD) birth weight standard deviation score (BWSDS) per gestational 
age (GA) group calculated with a Canadian and a Swedish growth reference.
In univariate logistic regression, all variables that reflected growth restriction at birth 
were highly significant as risk factors for later ROP treatment for infants born at GA 
≥26 weeks. These variables included low BWSDS and SGA (both growth references) 
as well as severe growth restriction (Canadian reference)(Table 2, Paper III).
In multivariate logistic regression analysis, including an interaction term (which 
allowed different associations with BWSDS for infants born at GA <26 weeks or 
GA ≥26 weeks), we found that independent of which growth reference used, low 
BWSDS was a risk factor for later ROP treatment for all infants (Table 3, Paper III). 
Hence, in infants born with a GA <26 weeks, the odds of requiring treatment were 
reduced by 20–28% for every additional 1 SDS increase in BWSDS. For infants 
born at GA ≥26 weeks, there was a major reduction of 44–59% for every additional 
1 SD increase in BWSDS (Figure 3, Paper III) (Table 3).
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Table 3. Example of how the odds for ROP treatment differ depending on the infant’s 
birth weight standard deviation score (BWSDS) and gestational age (GA).
Female infant 
GA 24 wks+0 day
31% prevalence of
ROP treatment*
(OR=0.80)
Female infant
GA 26 wks+0 day
7% prevalence of
ROP treatment*
(OR=0.56)
BWSDS
(Swedish Reference)
BW (g) Odds for 
ROP treatment*
BW (g) Odds for 
ROP  treatment*
2.0 825 20% 1110 2%
1.0 750 25% 1040 4%
0.0 670 31% 920 7%
-1.0 610 39% 820 12%
-2.0 510 48% 720 22%
*Prevalence of ROP, Holmström et al., SWEDROP
Nutritional intake as a risk factor
In the EXPRESS cohort, there were 498 surviving infants with complete nutritional 
data. The macronutrient intake during the first 28 days of life was low (mean±SD): 
102±14 kcal/kg/d of energy, 3.0±0.4 g/kg/d of protein, 11.2±1.1 g/kg/d of carbohy-
drates, and 4.8±1.2 g/kg/d of fat. The mean energy intake during the first four weeks 
in infants developing severe ROP was 97±13.5 kcal/kg/d compared to 108±13.5 
kcal/kg/d in infants not developing ROP (Table 1, Paper IV) (Figure 17).
In logistic regression analyses that were adjusted for GA and BW, we found that low 
intake of energy, fat, and carbohydrates during the first 28 days of life were associ-
ated with an increased risk of developing severe ROP (Table 2, Paper IV).
Figure 17. Energy intake during the first four weeks of life in correlation to ROP disease 
(EXPRESS n=498).
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When estimating the nutritional intake in multiple logistic regression analyses that 
included recognized risk factors such as GA, BW, postnatal weight change, CRIB 
score, duration of mechanical ventilation, blood transfusions, proportions of enteral 
fluids, steroid and antibiotics treatment, PDA, and IVH, we found that energy in-
take remained as an independent risk factor for severe ROP together with BW, dura-
tion of mechanical ventilation, and amount of blood transfusions (Table 4, Paper IV).
Table 4. Significant risk factors for severe retinopathy of prematurity (ROP) in multi-
variate logistic regression analysis (n=498).
OR 95% CI
Energy intake1, 0–28 days 0.76** 0.65–0.90
Blood transfusions2, 0–28 days 1.17* 1.02–1.33
Mechanical ventilation3, days 1.03* 1.00–1.06
Body weight4, g 0.75*** 0.65–0.87
110 kcal/kg/day increments
210 ml/kg per week increments
3One-day increments
4100 g increments
*p<0.05, **p<0.01, ***p<0.001
Consequently, every increase in energy intake of 10 kcal/kg/day during the first 28 
days of life could lower the odds of developing severe ROP by 24%. 
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Discussion
Major findings
The studies in this thesis all contribute to research that aims to identify novel risk 
factors for ROP. With accessibility to web-based programs such as WINROP, the 
possibility of more individualized ROP screening is not only promising, it is already 
available. Using WINROP, we confirmed that poor postnatal weight gain is a major 
risk factor for severe ROP, although WINROP can be refined further for extremely 
preterm infants to increase the specificity (e.g. reassessment of the WINROP alarm).
Our results further indicate that estimations of risk for severe ROP can be improved 
by including BWSDS and weight or weight SDS at first detection of ROP. Better 
risk estimates provide a basis for reducing the number of eye examinations in infants 
with low risk for ROP while increasing vigilance for infants who are at high risk for 
ROP.
Our results also indicate that low energy intake during the first four weeks of life is 
an independent risk factor for severe ROP. Adequate provision of energy intake dur-
ing the first four weeks of life may be an effective method to reduce the risk of severe 
ROP in extremely preterm infants.
WINROP identifies high-risk infants in the EXPRESS cohort
When validating the WINROP algorithm in the EXPRESS cohort, we found that, 
as in previous WINROP studies, the WINROP alarm signal was early, i.e. at a me-
dian of 3 weeks after birth. As expected, WINROP also signaled an alarm several 
weeks to months before the time of treatment, with a median time of 9 weeks from 
alarm to treatment. Identifying infants at high risk of severe ROP several weeks 
before the onset of ROP possibly provides the neonatologist with an opportunity 
to investigate postnatal preventive strategies. In particular, increased early nutrition 
may modify the course of ROP, as we proposed in Paper IV.
The sensitivity of WINROP in the EXPRESS cohort was high—95.7%—and was 
comparable to that found in previous WINROP studies. However, the specificity 
was 23.9%, which is lower than in previous studies98,147,150-152. The low specificity in 
the EXPRESS cohort prompted us to look for additional variables to identify infants 
at risk of developing ROP requiring treatment (ROP type 1). Many or even most 
of the extremely preterm infants had poor postnatal weight development, and, not 
surprisingly, 78% had a WINROP alarm. When analyzing infant weight at the time 
of the alarm in relation to GA and alarm week, we found that there appeared to be 
a “safe weight” at the time of the WINROP alarm. That is, if an infant’s weight at 
the time of the WINROP alarm was above this safe weight cut-off, the infant would 
not develop ROP requiring treatment. When we conducted an inter-sample reas-
sessment of the WINROP alarm using these alarm weight cut-offs, the specificity of 
WINROP in the EXPRESS cohort improved from 23.9% to 35.0% (unpublished 
data). This is a promising sign that WINROP can be improved and developed fur-
ther, and we plan to validate the safe alarm weight cut-off in other cohorts as well.
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The mean number of eye examinations per infant in the EXPRESS cohort was 11. 
Infants without a WINROP alarm and ROP had a mean of 6 eye examinations. 
In EXPRESS, we found that if an infant had not received a WINROP alarm, they 
could safely be screened for ROP on three occasions: PMA 31 weeks, PMA 33 
weeks, and PMA 36 weeks. Such screening would ensure that no infants developing 
ROP type 1 would have been missed. This proposed screening schedule would have 
reduced the number of screening examinations by 50% for an infant with no ROP 
and no WINROP alarm, a reduction that would not only reduce medical costs but 
which would be substantially beneficial for that particular infant’s well-being.
In the EXPRESS cohort, 47 infants developed ROP type 1 that fulfilled the treat-
ment criteria, but 66 infants were treated. This reflects a well-known clinical prob-
lem: A diagnosis of ROP type 1 is challenging for the ROP screening ophthalmolo-
gist156. Many extremely preterm infants will develop proliferative severe ROP, but 
for some, the disease will resolve spontaneously without any treatment. It is difficult 
to distinguish these infants since the treatment criteria rely heavily on the diagnosis 
of plus-disease, which is based on subjective judgment and shows great variability 
between clinicians. In settings where WINROP is used routinely, as in the city of 
Gothenburg, the clinical experience is that if an infant has not received a WINROP 
alarm, the chance that the ROP disease will resolve spontaneously is great. This is 
reassuring for the ophthalmologist and means that overtreatment can be reduced.
In the EXPRESS cohort, two infants that developed ROP type 1 and received treat-
ment for ROP were not detected by the WINROP system. Notably, both of these 
two infants had severe clinical courses. Thus, clinical judgment regarding the in-
fants’ risk of developing ROP requiring treatment should always overrule the WIN-
ROP outcome. The accuracy of weight measurements in critically ill infants should 
also be questioned, because in some cases, the measured weights might not reflect 
the infants’ growth. Weight measurements that do not correspond to the infants’ 
actual growth could be caused by, e.g., edema or by the medical equipment attached 
to a critically ill infant.
It should be pointed out that the majority of infants screened for ROP are not ex-
tremely preterm. In fact, only about 5% of preterm infants born worldwide are clas-
sified as extremely preterm5. However, since extremely preterm infants have a high 
risks of developing severe ROP, these infants tend to generate a substantial workload 
in ROP screening processes. Furthermore, extremely preterm infants are the most 
vulnerable, and in ROP screening, they often suffer from the side effects of mydri-
atic eye drops and from the discomfort of the examination itself; thus, reducing the 
number of eye examinations would be especially beneficial for the extremely preterm 
infant.
Variables at first detection of retinopathy of prematurity 
are useful predictors
For the first time, to our knowledge, we established in Paper II that infants that were 
later treated for ROP had a significantly lower median weight (1540 g vs. 1995 g; 
p<0.001) and lower median WSDS (-1.18 vs. -2.19; p<0.001) at the time of first de-
tection of ROP compared to infants that did not develop ROP requiring treatment. 
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We also confirmed previously reported findings that a low PMA at first detection of 
ROP is a risk factor for the development of severe ROP39.
Low weight and low WSDS at first detection of ROP are variables that could reflect 
low GA and/or poor pre- or postnatal growth. Accordingly, they could help predict 
an infant’s ability to handle the emerging ROP. Measuring the infants’ weight at 
first detection of ROP could be a simple way to assess poor weight gain, especially 
in clinical settings where complementary screening tools for poor postnatal weight 
gain such as WINROP are not available.
In Paper II, we also found that no infant weighing >2000 g or with a WSDS above 
-1.13 SDS at first detection of ROP was treated later on. We intend to further evalu-
ate whether these weight limits at first detection of ROP are applicable in other 
cohorts.
Low birth weight is a risk factor for retinopathy of prema-
turity that depends on gestational age at birth
In Paper III, we established that low birth weight is a risk factor for severe ROP in 
preterm infants and that the impact of the growth deficit at birth is dependent on 
the GA at birth. Low birth weight as a risk factor for ROP has been assessed previ-
ously in many studies, but the results have been contradictory6,59,78,81-85. The results 
presented in Paper III help clarify these contradictory results.
To try to determine the possible reasons for the inconsistences in the literature, we 
calculated the birth weight deficit using two different growth charts. In addition, 
we defined prenatal growth restriction several ways, plus we divided the infants into 
pair-wise GA groups to correct for differences in results that were due to the infants’ 
degree of immaturity. Our results showed that low birth weight, regardless of the 
growth reference, is a risk factor for severe ROP for preterm infants; however, the 
impact of growth deficit is dependent on GA at birth. Consequently, Paper III helps 
explain previous inconsistences.
We detected a shift in the impact of low BWSDS at around GA 26 weeks: For in-
fants born at GA <26 weeks, the risk of requiring treatment for ROP was reduced 
by 20–28% (depending on the growth reference used) for every 1 SD increase in 
BWSDS. For infants born at GA ≥26 weeks, there was a 44–59% reduction for 
every 1 SD increase in BWSDS.
In clinical practice, this would suggest that a growth-restricted newborn (BW -2 
SDS) born at GA 26 weeks has a risk of developing severe ROP that is equal to that 
of a well-nourished infant (BW 2 SDS) born at GA 24 weeks. Currently, BWSDS is 
rarely calculated or available at the start of an infant’s ROP screenings. Thus, calcu-
lating BWSDS could be another simple procedure that is part of a new approach to 
individualize ROP screening.
We recommend the use of the BW deficit as calculated in BWSDS rather than the 
use of strict cut-offs like SGA. Calculating a deficit in BWSDS offers a continuum 
estimation of growth deficit as a risk factor. In our study, we obtained different 
results in terms of whether or not SGA was a risk factor for severe ROP depending 
on the definition of SGA and depending on the growth reference we used. This is 
unfortunate and makes the use of SGA less definitive.
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The mean number of eye examinations per infant in the EXPRESS cohort was 11. 
Infants without a WINROP alarm and ROP had a mean of 6 eye examinations. 
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and no WINROP alarm, a reduction that would not only reduce medical costs but 
which would be substantially beneficial for that particular infant’s well-being.
In the EXPRESS cohort, 47 infants developed ROP type 1 that fulfilled the treat-
ment criteria, but 66 infants were treated. This reflects a well-known clinical prob-
lem: A diagnosis of ROP type 1 is challenging for the ROP screening ophthalmolo-
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In the EXPRESS cohort, two infants that developed ROP type 1 and received treat-
ment for ROP were not detected by the WINROP system. Notably, both of these 
two infants had severe clinical courses. Thus, clinical judgment regarding the in-
fants’ risk of developing ROP requiring treatment should always overrule the WIN-
ROP outcome. The accuracy of weight measurements in critically ill infants should 
also be questioned, because in some cases, the measured weights might not reflect 
the infants’ growth. Weight measurements that do not correspond to the infants’ 
actual growth could be caused by, e.g., edema or by the medical equipment attached 
to a critically ill infant.
It should be pointed out that the majority of infants screened for ROP are not ex-
tremely preterm. In fact, only about 5% of preterm infants born worldwide are clas-
sified as extremely preterm5. However, since extremely preterm infants have a high 
risks of developing severe ROP, these infants tend to generate a substantial workload 
in ROP screening processes. Furthermore, extremely preterm infants are the most 
vulnerable, and in ROP screening, they often suffer from the side effects of mydri-
atic eye drops and from the discomfort of the examination itself; thus, reducing the 
number of eye examinations would be especially beneficial for the extremely preterm 
infant.
Variables at first detection of retinopathy of prematurity 
are useful predictors
For the first time, to our knowledge, we established in Paper II that infants that were 
later treated for ROP had a significantly lower median weight (1540 g vs. 1995 g; 
p<0.001) and lower median WSDS (-1.18 vs. -2.19; p<0.001) at the time of first de-
tection of ROP compared to infants that did not develop ROP requiring treatment. 
49
Discussion
We also confirmed previously reported findings that a low PMA at first detection of 
ROP is a risk factor for the development of severe ROP39.
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in clinical settings where complementary screening tools for poor postnatal weight 
gain such as WINROP are not available.
In Paper II, we also found that no infant weighing >2000 g or with a WSDS above 
-1.13 SDS at first detection of ROP was treated later on. We intend to further evalu-
ate whether these weight limits at first detection of ROP are applicable in other 
cohorts.
Low birth weight is a risk factor for retinopathy of prema-
turity that depends on gestational age at birth
In Paper III, we established that low birth weight is a risk factor for severe ROP in 
preterm infants and that the impact of the growth deficit at birth is dependent on 
the GA at birth. Low birth weight as a risk factor for ROP has been assessed previ-
ously in many studies, but the results have been contradictory6,59,78,81-85. The results 
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To try to determine the possible reasons for the inconsistences in the literature, we 
calculated the birth weight deficit using two different growth charts. In addition, 
we defined prenatal growth restriction several ways, plus we divided the infants into 
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BWSDS. For infants born at GA ≥26 weeks, there was a 44–59% reduction for 
every 1 SD increase in BWSDS.
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The impact of nutrition on retinopathy of prematurity
When evaluating nutritional intake in the EXPRESS cohort (Paper IV), we found 
that the mean energy intake during the first four weeks of life was 102 kcal/kg/day, 
which was distinctly lower than the lowest estimated requirement of 105–110 kcal/
kg/day for preterm infants118. Low intake of energy, fat, and carbohydrates correlated 
with an increased risk of severe ROP. Our results indicate that an increase in energy 
intake of just 10 kcal/kg/day during the first four weeks of life could reduce the risk 
of developing severe ROP by 24% (OR=0.76). Similar findings were also reported 
in a study by VanderVeen et al.52 However, under-nutrition might be due to feeding 
difficulties and to a reduced ability to assimilate nutrients, making prevention via 
nutrition somewhat difficult. Though challenging, achieving required energy and 
nutrient intake from parenteral and enteral nutrition may be feasible through the use 
of concentrated parenteral nutrition solutions, early fortification of breast milk and 
daily monitoring of growth and calculated nutrient intakes.157
Strengths and limitations of the studies
Strengths
A major strength of this thesis was the large study cohorts. The EXPRESS cohort 
was nation-based and only included extremely preterm infants. Thus there was a 
substantial number of very low GA infants, which makes the results robust. Weekly 
weight measurements were performed throughout the neonatal period of all infants, 
making the longitudinal weight data reliable. Careful validation of data was per-
formed using check routines for correctness of data input to the systems. Check 
routines also included an additional validation by a second statistician.
Limitations
One limitation of all of the included studies is that they were retrospective chart 
reviews. In prospective studies where a research protocol has been developed the risk 
of missing data is considered to be minor in comparison to retrospective studies. In 
our studies some infants had missing data or did not complete their study course 
and therefore were excluded. Infants were mainly excluded due to missing weekly 
weight measurements. The number of infants that were excluded differed depending 
on the study design. Unfortunately, we can only speculate about the causes for the 
missing weight measurements, but severe morbidity is often a reason that weight 
measurements are not performed routinely. For example, in Paper I we found that 
the excluded infants had lower GA as well as lower BW compared to infants with 
complete weekly weight measurements.
Another limitation of the studies is that when evaluating weight at birth and post-
natal growth as risk factors for severe ROP, other established risk factors and comor-
bidities were not considered.
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Conclusions
The work in this thesis identified several new growth variables of preterm infants 
that could be used as predictors of ROP as part of a new approach to individualized 
ROP screening. By calculating an infant’s BWSDS, which is rarely done on a routine 
basis, we could determine an additional risk factor at birth. The web-based surveil-
lance system WINROP, which identifies infants with poor postnatal weight gain, 
can identify infants at high risk of ROP, usually within the first few weeks of life. 
By calculating an infant’s WSDS when ROP is first detected, we hope to get some 
information about the future course of the ROP (Figure 18). Early identification of 
high-risk infants might provide neonatologists and ophthalmologists with an indica-
tion that special attention is warranted.
By using a new approach to ROP screening and by developing new surveillance 
systems that complement established ROP-screening guidelines, we can significantly 
improve the identification of infants who are at high risk for severe ROP, thus spar-
ing fragile infants unnecessary painful examinations and additional suffering.
Figure 18. New approaches to identifying an infant who needs treatment for retinopathy 
of prematurity (ROP) are exemplified by monitoring the changes in weight over time of 
a preterm infant.
Future perspectives
In the near future, we aim to further refine the WINROP surveillance system based 
on the findings in this thesis. Our findings indicate that we can significantly improve 
the specificity of WINROP, especially for extremely preterm infants, by further as-
sessing infant weight when there is a WINROP alarm. We also aim to validate and 
to further assess whether weight cut-offs at first detection of ROP can be used safely 
as predictors of the course of ROP.
WINROP signals with an early alarm, and this may allow time to initiate new 
preventive interventions. We intend to evaluate whether increased nutrition after a 
WINROP alarm can prevent the development of ROP.
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Since ~2010, most NICUs have made changes in their nutritional practices: nutri-
tional intake have been calculated on more of a routine basis, more concentrated 
parenteral solutions have been used, and there has been earlier fortification of hu-
man milk. All of these changes are intended to optimize the nutritional intake of 
preterm infants. We plan to compare nutritional intake, growth, and ROP out-
come in the EXPRESS cohort with those of a more recent cohort of preterm infants 
(Umeå and Stockholm 2009–2012).
The WINROP database gives us access to longitudinal weight data from over 3000 
infants, and we plan to further analyze these data. To our knowledge, no one has 
previously reported differences in growth patterns in relation to ROP according to 
infant GA. If poor postnatal weight gain as a risk factor for ROP differs according 
to GA, this information could be useful for further individualizing ROP screening.
Finally, we have just begun to analyze preliminary data in a follow-up study of the 
EXPRESS infants and their vision outcomes when they are at school age, i.e. 6.5 
years old. The preliminary data indicate that extremely preterm infants have signifi-
cantly more ophthalmologic abnormalities than age-matched controls.
Figure 19. Mio: “ looking towards the future”. ©Stina Fahlén
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